ArticleOncoTargets and therapy2016
Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- The MCU-MECOM Axis Orchestrates Glioblastoma Progression by Remodeling Mitochondrial Dynamics and Quality Control via MAMs.International journal of biological sciences · 2026Article
- Whole-Genome Sequencing Reveals a NovelCancers · 2025Article
- Article
- Article
- Curcumin against gastrointestinal cancer: A review of the pharmacological mechanisms underlying its antitumor activity.Frontiers in pharmacology · 2022Review
- EVI1 in Leukemia and Solid Tumors.Cancers · 2020Review
- Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway.Journal of Cancer · 2020Article
- Ecotropic viral integration site 1 regulates EGFR transcription in glioblastoma cells.Journal of neuro-oncology · 2019Article
- Ecotropic virus integration-1 and calreticulin as novel prognostic markers in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2019Article
- Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics.Diagnostics (Basel, Switzerland) · 2019Article
- Neural progenitor fate decision defects, cortical hypoplasia and behavioral impairment in Celsr1-deficient mice.Molecular psychiatry · 2018Article
- Prognostic Significance of Zinc Finger E-Box-Binding Homeobox Family in Glioblastoma.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Prognostic Significance of TNFR-Associated Factor 1 and 2 (TRAF1 and TRAF2) in Glioblastoma.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Overexpression of ecotropic viral integration site-1 is a prognostic factor of lung squamous cell cancer.OncoTargets and therapy · 2017Article
- Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.PloS one · 2017Article
- Altered long non-coding RNAs expression in normal and diseased primary human airway epithelial cells exposed to diesel exhaust particles.Inhalation toxicologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of MECOM in glioblastoma multiforme (GBM) has not been well elucidated. PATIENTS AND
methodsOur study enrolled 86 resected samples of GBM in three medical centers. We detected the expression of MECOM in all the 86 samples by immunohistochemistry and compared the difference of MECOM mRNA between tumor tissues and adjacent tissues with real-time polymerase chain reaction. With immunoblotting, we detected the MECOM expression in different GBM cell lines. Moreover, we analyzed the correlation between MECOM expression and clinicopathologic factors with chi-square test, and evaluated the prognostic value of MECOM with univariate and multivariate analysis.
resultsIn GBM tissue, the percentage of MECOM high expression is 41.9% (36/86). The mRNA of MECOM in tumor tissues is remarkably higher than that in adjacent tissues, indicating the oncogenic role of MECOM in GBM. MECOM exists in all the detected cell lines with different abundance. Moreover, MECOM is correlated with poorer overall survival rate (P=0.033) and can be identified as an independent prognostic factor in GBM (P=0.042).
conclusionMECOM could be considered as an independent prognostic factor in GBM, predicting it as a potential and promising molecular drug target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.